
- Acute Myeloid Leukemia (AML)
- Aplastic Anemia
- Myelodysplastic Syndromes (MDS)
- Myeloproliferative Neoplasms (MPN)
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Pediatric
I am a physician-scientist who sees patients in clinic with disorders of clonal hematopoiesis and myeloid cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). My clinical and research interests focus on RNA regulation in hematologic malignancies. Specifically, I investigate how mutations in splicing factors affect RNA processing and contribute to disease progression. These genetic mutations can occur at any stage of life, leading to complex disorders that are often challenging to diagnose and treat.
In the laboratory, we utilize advanced genomic technologies, such as RNA sequencing and ribosome profiling, to explore how disrupted RNA processing drives malignancy. The primary goal of this research is to uncover novel therapeutic targets and develop innovative immunotherapy approaches aimed at improving patient outcomes in high-risk myeloid malignancies. By examining these questions through the lens of RNA regulation, our work aims to bridge clinical care and fundamental research to better understand and treat disorders of clonal hematopoiesis and myeloid cancers.
- accepting new patients
